ROBINUL FORTE Rx
Generic Name and Formulations:
Glycopyrrolate 2mg; dye-free tabs.
Indications for ROBINUL FORTE:
Adjunct in peptic ulcer.
1–2mg 2–3 times daily; max 8mg daily.
Glaucoma. Unstable cardiovascular status. Asthma. GI or urinary tract obstruction. Paralytic ileus or intestinal atony. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
Reflux esophagitis. Autonomic neuropathy. Impaired hepatic or renal function. Cardiovascular disease. Tachycardia. Hypertension. Hyperthyroidism. High environmental temperature. Diarrhea. Elderly. Debilitated. Pregnancy (Cat.B). Nursing mothers.
Concomitant antacids may inhibit absorption. Cyclopropane anesthetics may cause arrhythmias. Additive anticholinergic effects with other anticholinergics, narcotic analgesics, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics.
Anticholinergic effects (e.g., dry mouth, blurred vision, constipation).
Inj (vials) Single dose 1mL—25
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry